Celsion Corporation (NASDAQ:CLSN) Unveils An Update On Its Phase I/II OVATION 2 Study

Celsion Corporation (NASDAQ:CLSN) has been focusing on its  Phase I/II OVATION 2 Study that involved GEN-1 in patients struggling with advanced ovarian cancer. The company is pleased to unveil the study’s updates, in which case it has highlighted interim observations.

Focusing on the study

GEN-1 refers to Celsion’s DNA-mediated interleukin-12 (IL-12) immunotherapy, which is fundamentally manufactured in the company’s delivery system platform known as TheraPlas.

The OVATION 2 Study targets patients diagnosed with Stage III/IV ovarian cancer and seeks to handle the situation using GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT).

Cancer is a deadly condition that continues to claim many lives worldwide, and there is a need to find a remedy as soon as possible. NACT’s design is such that it functions to shrink cancer to facilitate better treatment. In other words, there is a need to shrink cancer in such a way that it is possible to undertake the optimal surgical removal safely and s easily.

Patients get subjected to an elaborate treatment process

According to the company, the patients must undergo interval debulking surgery. After the surgery, the patients experience the three chemotherapy adjuvant cycles. The patients need to understand the process well to make more informed decisions. For instance, they must be ready for the nine additional weekly GEN-1 treatments that follow. The medical experts seek to introduce delays in cancer progression and also boost chances of overall survival.

Celsion Corporation is a vigilant company that continues channeling its efforts and resources in developing solutions that inspire hope among cancer patients. The company has so far managed to enroll 34 patients, representing one-third of the 110 patients anticipated total.

Celsion exudes confidence in the OVATION 2 Study, outlining that it stands a chance to become a game-changer in cancer treatment. The business is pleased to announce that it has already gotten about 27 patients in their interval debulking surgery and that the results might be quite interesting to most people.